Directory · CH
Biotechnology Research in Switzerland
A register of firms and the professionals working at them in the Biotechnology Research sector based in Switzerland. Browse the public index, then filter or export on Kipplo.
Companies
522 on file
Basilea Pharmaceutica
Basilea is a commercial-stage biopharmaceutical company founded in and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
51 to 200 staff
Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S, Europe, Asia and other international markets.
1001 to 5000 staff
Infors Ht
INFORS HT, a Swiss-based company, bringing 60 years of expertise to bioprocessing research and development. We specialize in bioreactors, incubator shakers, and bioprocess software, offering scalable solutions for microbial and animal cell cultures. With advanced monitoring, control, and data logging, we focus on parallel systems and deliver high-quality, flexible solutions while maintaining close customer relationships.
201 to 500 staff
Ac Immune
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
51 to 200 staff
Mindmaze
MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.
51 to 200 staff
Kuhner Shaker
Kuhner AG is the leading developer and manufacturer of shaking machines for the international market. Founded in 1949 by Mr Adolf Kühner, this family business is now led by his son Markus Kühner. From bench top shakers to large scale industrial shakers, Kuhner offers machines of the highest quality. We endeavour to understand your science and cultivation needs to ensure solutions accelerating your time to market and elevating your results. We commit to earning the trust of our clients and establishing relationships which will span decades. Alongside the core shaker business, Kuhner AG is also a distributor for premium brands of laboratory equipment in Switzerland.
51 to 200 staff
Ubc
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and ultimately, drive better patient outcomes.
1001 to 5000 staff
Excellgene Sa
Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.
51 to 200 staff
Lunaphore A Bio-Techne Brand
Lunaphore Technologies S.A, a Bio-Techne brand, is a Swiss-based life sciences company founded in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. Community guidelines available here: https://link.lunaphore.com/guidelines
51 to 200 staff
Moonlake Immunotherapeutics Nasdaq Mltx
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
11 to 50 staff
Packgene Biotech, Inc
PackGene is a world-leading AAV vector packaging CRO and CDMO. Founded in Massachusetts, USA, PackGene now has offices in Boston, Houston and Zurich. We work with customers to support gene therapy programs from early-stage R&D, preclinical development, to IND studies. Our mission is to accelerate gene therapy product development by providing an integrated one-stop solution including plasmid, viral vector, fill-finish and QC analytical services for the gene therapy industry.
201 to 500 staff
Selexis Sa
KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings.
1001 to 5000 staff
Cutiss Ag
CUTISS is a late-stage clinical TechBio company and the only one transforming skin surgery and advanced dermatology with revolutionary skin tissue therapeutics. We are developing the first BIO personalized and automated skin tissue therapy for patients requiring skin surgery for a large spectrum of indications- from severe burns to reconstructive and aesthetic procedures. Our lead product denovoSkin™ is a first-in-class, bioengineered, personalized skin tissue therapy designed to improve patient outcomes and redefine the standard of care in skin surgery. Currently in Phase 3 clinical trials in the European Union, it has Orphan Drug Designation for the treatment of burns from Swissmedic, the EMA, and the US FDA. CUTISS is also pioneering the TECH automation of skin tissue bioengineering, developing the world’s first machine capable of fully automating the manufacturing process. This breakthrough ensures scalability, accessibility and cost-efficiency, and supports attractive unit economics. Our proprietary TECHBIO platform offers growth opportunities in other areas of regenerative medicine, from space research to non-healthcare applications (tissues for industry). Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) and University Children’s Hospital. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over $90 million from private investors, family offices and public bodies.
11 to 50 staff
Cytosurge
Cytosurge develops innovative research solutions using its proprietary FluidFM® technology for precise single-cell manipulation thereby fostering advancements in understanding cellular processes such as the ones that drive cancer. With the FluidFM OMNIUM platform, single-cell extracts, or “biopsies” can be taken from living cells, enabling live-sequencing and temporal transcriptomics analysis. Additionally, the CellEDIT Service provides high-quality genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, thereby enabling longer and healthier lives through precision gene engineering. The Company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing, and empowering genetic engineers to realize their visionary concepts.#FluidFM #AFM #mRNA #scRNAseq #LiveSeq #Transcriptomics #Genomics #CellEDIT #CRISPR #GeneEditing #GeneEngineering #CRISPRGeneEditing #GeneticEngineering #CellLineDevelopment #DNAmodifications
11 to 50 staff
Socorex Isba Sa
Socorex Isba SA is a reputable Swiss manufacturer of precision dosing instruments. Thanks to a high technical know-how, to the professionalism of its teams and to a healthy management of its growth along the past 60 years, Socorex is now a recognized player for liquid handling instruments for the laboratory and automatic syringes for serial animal injections.
11 to 50 staff
3brain Ag
3Brain developed and distributes the world’s first commercial CMOS-based high-resolution Microelectrode Array (MEA), a Biosensor integrating thousands of tiny electrical sensors in a small area. Our Biosensor allows non-invasive (in vitro) investigations of electrogenic cells, such as neurons, cardiac and muscle cells. The technology can be used to investigate electroactive cells' fundamental properties (e.g, neural code for learning and memory), to study and find new treatments to different types of diseases (e.g. Alzheimer and epilepsy) and to assess compounds/chemical toxicity.
11 to 50 staff
Evolva
At Evolva we believe in applying technology platforms, such as fermentation, to help resolve sourcing bottlenecks in nature. These enable us to provide products that can contribute to health, wellbeing and sensory enjoyment. We research, develop and commercialize high quality, affordable, ready-to-formulate ingredients that are based on nature and are available at all times, in any quantity. With around 55 employees from 15 nationalities we promote an interdisciplinary and inclusive working environment.
51 to 200 staff
Hedera Dx
Liquid biopsies provide better therapy options for more patients. Hedera Dx is on a mission to provide the next billion people with access to modern cancer care. We specialize in clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. Our culture is based on thinking different, modern and human, fostering a dynamic and innovative work environment. Join us on hederadx.com to learn more!
11 to 50 staff
Hse Ag
HSE•AG: Engineering Precision for Life Science Innovation At HSE•AG, we empower breakthrough discoveries in life science and diagnostics by delivering tailored, high-performance engineering solutions. From concept to market, we partner with leading companies to transform complex biological workflows into scalable, automated systems. Our Expertise Includes- Laboratory automation and system integration - OEM product development and industrialization - Mechanical and software engineering - Instruments, software and consumable development - Life cycle and risk management - Application-driven design and concepts We bridge biological insight with engineering excellence, designing technologies that accelerate discovery, improve reproducibility, and streamline diagnostics. Our solutions are optimized for real-world use in research labs, diagnostic settings, and manufacturing environments. At HSE•AG, we don’t just solve engineering problems—we help you create measurable impact. Let’s shape the future of life sciences, together.
51 to 200 staff
Maxwell Biosystems
Founded in September 2016 as an ETH Zürich spin-off, MaxWell Biosystems is a technology leader providing instrumentation and solutions to boost scientific research and development in neurosciences, stem cell and tissue engineering, ophthalmology, and other fields involving electrogenic cells. MaxOne (single-well) and MaxTwo (multi-well) are easy-to-use systems that equip scientists with the ability to record electrical signals of neurons in in-vitro 2D and 3D models at network, cellular, and subcellular levels. MaxWell Biosystems’ main goal is to be a trusted partner to all users and collaborators, for a greater cause, of advancing scientific breakthroughs and for achieving faster and more effective drug discovery, through our products, solutions, and expertise.
51 to 200 staff
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.
51 to 200 staff
Polpharma Biologics
Polpharma Biologics is a biopharmaceutical company headquartered in Switzerland that develops, manufactures and commercializes biosimilars for global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch. Our international team of senior experts has proven experience in program leadership, regulatory strategy, clinical oversight, CMC integration, device development and quality. Working with trusted CDMOs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners bring these medicines to patients worldwide. Our mission is simple: to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development.
1001 to 5000 staff
Reploid
REPLOID is a globally active, publicly traded biotechnology company that converts organic waste (such as food waste) into high-quality proteins, fats, and fertilizers by breeding black soldier flies (Hermetia illucens) in order to promote industrial and regional circular economies, reduce emissions, and conserve resources by building and selling decentralized, highly automated modular insect farms. The goals are a global net-zero strategy, the circular and sustainable recycling of waste into valuable raw materials for animal feed, especially for dogs, cats, chickens, and fish, as well as high-quality hybrid biofertilizers that are produced and sold in collaboration with partners.
51 to 200 staff
Rgcc International
At RGCC, we are at the forefront of revolutionizing healthcare through personalized solutions for cancer and chronic diseases. Our commitment is global, aiming to provide personalized, accessible, diagnostic and therapeutic options to patients worldwide. Explore our innovative range of tests and therapies meticulously tailored for each patient's unique needs at rgcc-international.com.
51 to 200 staff
Vegalab
Vegalab is a global leader in formulating and manufacturing environmentally responsible natural agrobiologicals, cosmetic and medical products and devices, and medical cleaning products. Applying nano-encapsulation, micronization and in-vivo cultivation technologies in our proprietary formulations allows us to create powerful cost competitive products that support a healthier world. Our unyielding commitment to produce eco-safe, all natural products based on years of biological research and patented technology has positioned the company for rapid growth. We offer a full suite of all-natural bio-pesticides (insecticides and fungicides), soil amendments, fertilizers and plant nutrients. The results of these innovative products are multifold: increase farming/gardening productivity, decrease residue in crops, decrease waste and reduction in the overall chemical footprint on the land. Vegalab corporate headquarters are in Switzerland, with offices and distributors worldwide.
51 to 200 staff
Asceneuron Sa
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc.(JJDC) and Kurma Partners. For more information, please visit Further information:
1 to 10 staff
Bioversys Ag
BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ready), and tuberculosis (Alpibectir, Phase 2) in collaboration with GSK and a consortium from the University of Lille. BioVersys is located in the TechPark in the thriving biotech hub of Basel.
11 to 50 staff
Didata
DiData aims for innovating and facilitating your lab’s daily work. The smoothness and simplicity of DiData software will surprise you! It will increase your lab productivity; with a seamless and modern user interface that will make you more efficient.
11 to 50 staff
Numab Therapeutics Ag
Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. With over a decade of innovation, Numab has built a highly differentiated multispecific antibody platform integrating λ-cap™ and MATCH™ technologies, advanced Fc engineering, and integrated immunogenicity-reduction strategies. Leveraging deep in-house engineering expertise, Numab is advancing a diversified pipeline of multispecific antibodies with first- and best-in-class potential and has established a strong track record of strategic partnerships with leading pharmaceutical companies.
51 to 200 staff
Stalicla
STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.
11 to 50 staff
Swiss Bioquant Ag
Swiss BioQuant is a bioanalytical contract research organization (CRO) specialized in LC-MS/MS and ligand-binding assays and dedicated to scientific excellence. With a deep understanding of customer requirements, Swiss BioQuant is the bioanalytical laboratory of choice for pharmaceutical and biotechnology companies demanding scientific excellence, uncompromised quality, timeliness, honest and open communications. Swiss BioQuant offers customized LC-MS/MS and ligand binding assay method development, validation and sample analysis in a 21 CFR part 11 compliant environment for small and large molecules. The high level of our services allows us to effortlessly keep pace with the constantly increasing quality demands of renowned pharmaceutical groups, both in content and in documentation. Important prerequisites for our excellent service and quality standards (GLP) are represented by our continuous investments into employee training, documentation and instrumentation. Continuous audits or inspections throughout years convincingly document the success of our efforts in these fields. An automated data evaluation and reporting system as well as a validated electronic archiving system facilitates a reliable data management.
11 to 50 staff
Swiss Rockets Ag
The Swiss Rockets mission is to deliver outstanding results for patients, inventors, and investors. Founded in 2018 in Basel, Swiss Rockets is implementing a paradigm shift in healthcare. Cancer patients will benefit from new treatment therapies developed using innovative and disruptive methods. The Swiss Rockets team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine. We aim to set new paradigms in healthcare. Disruptive innovation in everything we do will allow us to deliver breakthrough treatments to patients with cancer. We conduct our business with the patients’ well-being in mind. Integrity, honesty, loyalty, and trust form the foundation on which we build our company and future success. All our investments, entrepreneurs, partners, and therapies always put the patients first. Our passion for people and patients makes us go at speed and with the power of rockets.
51 to 200 staff
Wyss Zurich
Wyss Zurich is a joint research and development center of the University of Zurich and the ETH Zurich, made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. hc. mult. Hansjörg Wyss. The mission of Wyss Zurich is to drive the clinical translation and technology transfer of outstanding scientific discoveries into new therapies for patients and breakthrough innovations in the emerging fields of Regenerative Medicine, Robotics and Medical Devices/Bionics Technologies. Wyss Zurich brings together some of the world’s leading experts to form multidisciplinary teams, pooling their knowledge and expertise.
51 to 200 staff
Adipogen Life Sciences
Adipogen Life Sciences is a leading research reagents company with its corporate headquarters is in San Diego, USA and the Operational headquarters and production in Switzerland. A motivated team of highly-skilled individuals develops and manufactures new products for the Life Science Research Market in its main areas of interest including obesity & diabetes, immuno-oncology, inflammatory diseases, innate immunity (inflammasome) and antimicrobial resistance. A major focus is on innovative and advanced ELISA Kits. In addition to the antibody and protein facilities, Adipogen Life Sciences owns chemical laboratories, enabling the company to isolate unique natural products and to develop new and innovative small molecules and rare antibiotics.
11 to 50 staff
Bigomics Analytics
At BigOmics, we are committed to empowering researchers in omics data analysis. Our Omics Playground is an intelligent omics data analysis platform that empowers biotech, pharma and academic teams to efficiently perform complex analysis and visualization. Why Omics Playground- Centralized and Searchable Data Management: Seamlessly manage and compare multiple datasets, accelerating discovery over time- Standardized, Reproducible Results: Apply consistent statistical frameworks across studies to ensure robust and reliable outcomes- Efficient and Scalable: Analyze large-scale datasets up to 10x faster, dramatically reducing time from raw data to insight- Publication-Ready Visuals: Export high-quality, customizable figures perfect for presentations, publications, and team collaboration. Governed self-service bioinformatics provides you with a powerful solution to fast-track your bioinformatics needs.
11 to 50 staff
Biocopy Ag
BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.
11 to 50 staff
Bionomous
Bionomous - the world's first provider of AI-powered solutions for screening, sorting and dispensing of small biological entities. We are an innovative, agile and conscious team of biologists and engineers working to provide you with an easy-to-use and customizable solution to free up valuable time and increase efficiency. Our patented technology was originally created to enable the mechanical sorting of zebrafish eggs. Now, we have adapted this technology to other small biological entities, such as other fish species used in research (killifish, medaka) and aquaculture, plant seeds and 3D cell constructs. Discover how we're automating tomorrow's biology on our website!
11 to 50 staff
Digital Innolab
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
10001+ staff
Eth
Zellbiologie
11 to 50 staff
Inofea Ag
INOFEA empowers enzymes. Enzyme stabilization and protection is INOFEA`s core business. We have developed an innovative and patented platform technology to provide enzymes with a protective shield. We unlock the full potential value of enzymes, providing a seamless level of enhanced properties, unlike any other existing technology. This makes your enzymes 10 times more stable and they can be re-used easily. Our highly resistant enzymes support Biocatalysis including bioconjugation, diagnostics (bioanalysis) or can be formulated as active ingredients. Our technology addresses a wide range of biotech applications for the industry and demonstrated substantial benefits to customers in pharma, food processing, specialty chemicals and consumer care.
1 to 10 staff
Interax Biotech
InterAx is redefining drug discovery by understanding treatment impact on diseases before pre-clinical trials begin, an analysis traditionally inaccessible to very early programs. Focusing on GPCR small molecules, the Deep Signal™ platform enables superior optimization of drug candidates, leading to differentiated drugs with higher efficacy and safety and lower clinical failure rates. InterAx’s three-asset portfolio demonstrates this impact, including a biologically differentiated GLP-1 asset that addresses the challenges seen with small-molecule competitors, a partnered GIP program, as well as an innovative ACKR3 program driven by unique target understanding. With four additional targets identified, the company is poised to expand into neurologic and autoimmune indications. Growing asset and platform partnerships highlight strong market traction, with future investments set to unlock GLP-1 value and scale the portfolio.
11 to 50 staff
Nemis Technologies
Elevating environmental monitoring standards! At NEMIS, we are setting new standards in environmental monitoring, helping your facility to manage food safety risks for Listeria, Salmonella, E. coli, and ATP. Our cutting-edge solutions are designed to proactively identify and address risks, transforming the way food safety is upheld in production environments. Our N-Light™ environmental monitoring solution sets a new standard for food safety, ensuring your facility remains audit-ready and free from contamination. Easy, Rapid, and Reliable Designed to integrate seamlessly into your existing processes, delivering fast and accurate pathogen detection. Advanced diagnostic tools and data management systems We help your quality control department to make more informed decisions through our advanced tools and intuitive dashboard. At NEMIS Technologies, we are pioneering new standards for microbiological excellence in both food safety and environmental monitoring. We believe in simplifying the process of ensuring safe food production, recognising that the right screening tools are crucial in preventing the spread of dangerous bacteria.
11 to 50 staff
Quartzbio, Part Of Precision For Medicine
QuartzBio is the Precision Medicine Intelligence Company. Our first-in-class Precision Medicine AI Agent Platform enables autonomous data ingestion and conversational insights across the precision medicine value chain. We're transforming the way precision medicine teams work with 360° intelligence. Powered by a network of domain-specific AI agents, QuartzBio’s solutions amplify the efforts of operations, translational, informatics, and IT teams in biopharma R&D, using AI-driven integration of biomarker, sample, and clinical data to create a unified, scalable data ecosystem. R&D teams can shorten time from data to insights, analytics, and visualizations, accelerating study close and time-to-market. We invite you to connect with our experienced, multidisciplinary, global team. After all, we connect people to processes, data, technology, and to each other. Our platform and solutions are designed to empower teams to work more quickly, efficiently, and effectively, replacing chaos and complexity with intuitive simplicity. With QuartzBio, you don’t have to be a data scientist to extract valuable insights from your data—all stakeholders can have access to insights, in real time. Send us a message, we’d love to chat!
51 to 200 staff
Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".
11 to 50 staff
Anaveon Ag
A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.
11 to 50 staff
Cdr-Life Inc
At CDR-Life, we are on a mission to transform antibody science into life-changing therapies. Our innovative T cell engager (TCE) platform, M-gager®, delivers therapeutics against challenging targets with unprecedented precision, speed and efficiency. For cancer patients, we are advancing a pipeline of potent and selective TCEs targeting intracellular and surface antigens that empower patients’ own immune systems to eliminate tumors, and our first program has entered the clinic. In autoimmune diseases, we're using this same breakthrough approach to reset overactive immune responses with pinpoint accuracy. Our platform combines optimized manufacturability with deep scientific expertise and cutting-edge engineering, enabling rapid translation from discovery to scalable production of these complex biologics. This integrated approach helps accelerate the journey from lab to patient treatment, making once-impossible therapeutic goals both achievable and deliverable at scale.
51 to 200 staff
Fasteris
DNA sequencing service provider based in Geneva, Switzerland. One of the longest experience in illumina Next-Generation DNA sequencing (NGS): L. Farinelli is co-inventor of DNA clusters (1996) and Fasteris was the first service provider in the world to acquire an illumina (then Solexa) sequencer in 2006. The company now uses PacBio Sequel IIe, illumina MiSeq, NextSeq and NovaSeq as well as ThermoFisher's Ion S5. Since 2007, Fasteris developed a broad range of applications to analyze genomes and transcriptomes, from library preparation to bioinformatics analyses- whole genome sequencing, de novo assembly- targeted re-sequencing and exomes- transcriptomes: ISO-seq and stranded RNA protocols- small RNAs- ChIP-SEQ to study protein-DNA binding sites- metagenomics: metabarcoding and full length 16S rRNA- short and long amplicons sequencing- custom projects such as Trypanosoma splice leader, phage display, etc. Genesupport SA, for Life Sciences Fasteris NGS services, provides ISO-17025 services for research laboratories, from small-scale projects to thousands of samples using automated protocols. We produced many thousands of NGS analyses under medical diagnostics conditions and ISO15189 accreditation. In 2013, Fasteris joined the Medisupport and in 2015 Medisupport joined Sonic Healthcare. In 2020 Fasteris merged with Medisupport Genetics labs to create Genesupport SA. Fasteris is the brand for Life Sciences, while Genesupport is used for Medical Genetics. Fasteris is co-author of tens of publications and cited in hundreds, see our website.
51 to 200 staff
Light Chain Bioscience Novimmune Sa
NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.
51 to 200 staff
